Nicotine Dependence in Schizophrenia: Clinical Phenomena and Laboratory Findings
The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The goal of this report is to examine the potential implications of the high prevalence of smoking in schizophrenia for our understanding of this illness. METHOD: A selective review of the relevant clinical and preclinical literature was conducted. The authors present a review of the clinical observations about smoking in schizophrenia, summarize the preclinical data about the complexity of the CNS nicotinic receptor family, and examine the modulatory effects of nicotine on neurotransmitter systems implicated in schizophrenia. RESULTS: Clinical data suggest that smoking in schizophrenia may represent an attempt to self-medicate symptoms of the illness. Preclinical findings support a potential role of nicotine in medicating negative symptoms in particular. Recent preclinical and clinical data suggest that schizophrenic patients have a primary defect in the CNS nicotinergic system that leads to abnormal sensory gating. The complexity of the neuromodulatory effects of CNS nicotinic systems on other neurotransmitter systems underscores both the scope and potential importance of continued advancement of research in this area. CONCLUSIONS: Despite increasing clinical research focused on the extremely high prevalence of smoking in schizophrenia, linkages to the prodigious preclinical data about nicotine and nicotinic receptors are largely unexplored. These linkages are likely to be very important. Integrating nicotine use into our clinical and basic models of schizophrenia leads to a more complex but more realistic representation of brain dysfunction in this illness. Understanding how and why schizophrenic individuals use nicotine may lead to the development of new treatments for both schizophrenia and nicotine dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Hollmann, M., & Heinemann, S. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.000335 · Cited by 3,975
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141
Carlsson, M., & Carlsson, A. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90108-m · Cited by 1,082
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Prevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058
Physiological Diversity of Nicotinic Acetylcholine Receptors Expressed by Vertebrate Neurons
McGehee, D. S., & Role, L. W. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.002513 · Cited by 1,022
Hippocampal synaptic transmission enhanced by low concentrations of nicotine
Gray, R., Rajan, A. S., Radcliffe, K. A., Yakehiro, M., & Dani, J. A. (1996) · Nature · doi:10.1038/383713a0 · Cited by 947
Cigarette smoking: implications for psychiatric illness
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.546 · Cited by 723
Cited by
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
de Leon, J., & Diaz, F. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.010 · Cited by 1,276
“, 1998; de Leon et al., 2002b) and one in Israel (Itkin et al., 2001) did not find significant differences in the mean FTND scores of schizophrenia versus mood-disordered smokers from same treatment settings. de Leon et al. (2002c) studied high nicotine dependence (FTND≥6) in samples of severely mentally ill smokers a…”
BackgroundMethodAntipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 822
Co‐Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders
Kalman, D., Morissette, S. B., & George, T. P. (2005) · The American Journal on Addictions · doi:10.1080/10550490590924728 · Cited by 594
Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum
Zhou, F.-M., Liang, Y., & Dani, J. A. (2001) · Nature Neuroscience · doi:10.1038/nn769 · Cited by 585
A neurobiological basis for substance abuse comorbidity in schizophrenia
Chambers, R. A., Krystal, J. H., & Self, D. W. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01134-9 · Cited by 548
Nicotine use in schizophrenia: The self medication hypotheses
Kumari, V., & Postma, P. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.02.006 · Cited by 468
The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour
Laviolette, S. R., & van der Kooy, D. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1298 · Cited by 456
Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic Agents
Siris, S. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1379 · Cited by 427
Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal
S. Watkins, G. F. K. (2000) · Nicotine & Tobacco Research · doi:10.1080/14622200050011277 · Cited by 424
Serious mental illness and physical health problems: A discussion paper
Robson, D., & Gray, R. (2007) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2006.07.013 · Cited by 411
The Epidemiology of Smoking: Health Consequences and Benefits of Cessation
Fagerstr??m, K. (2002) · Drugs · doi:10.2165/00003495-200262002-00001 · Cited by 378
Addressing tobacco among individuals with a mental illness or an addiction
Williams, J. M., & Ziedonis, D. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.03.009 · Cited by 359
George, T. P., Ziedonis, D. M., Feingold, A., Pepper, W. T., Satterburg, C. A., Winkel, J., Rounsaville, B. J., & Kosten, T. R. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1835 · Cited by 354
Abnormal Regulation of High Affinity Nicotinic Receptors in Subjects with Schizophrenia
Breese, C. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00121-4 · Cited by 345
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia
Martin, L., Kem, W., & Freedman, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1750-1 · Cited by 342
Sacco, K. A., Termine, A., Seyal, A., Dudas, M. M., Vessicchio, J. C., Krishnan-Sarin, S., Jatlow, P. I., Wexler, B. E., & George, T. P. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.649 · Cited by 330
The Diagnostic and Statistical Manual
Newnes, C. (2014) · De-Medicalizing Misery II · doi:10.1057/9781137304667.0017 · Cited by 324
Kelly, C., & McCreadie, R. G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1751 · Cited by 317
Assessing motivation to quit smoking in people with mental illness: a review
Siru, R., Hulse, G. K., & Tait, R. J. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02545.x · Cited by 301
Leonard, S., Adler, L. E., Benhammou, K., Berger, R., Breese, C. R., Drebing, C., Gault, J., Lee, M. J., Logel, J., Olincy, A., et al. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00677-3 · Cited by 300
Critical Factors in Gene Expression in Postmortem Human Brain: Focus on Studies in Schizophrenia
Lipska, B. K., Deep-Soboslay, A., Weickert, C. S., Hyde, T. M., Martin, C. E., Herman, M. M., & Kleinman, J. E. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.019 · Cited by 285
Laursen, T. M., Munk-Olsen, T., Agerbo, E., Gasse, C., & Mortensen, P. B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.61 · Cited by 271
Azam, L., Winzer‐Serhan, U. H., Chen, Y., & Leslie, F. M. (2002) · Journal of Comparative Neurology · doi:10.1002/cne.10138 · Cited by 260
Hall, S. M., & Prochaska, J. J. (2009) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.032408.153614 · Cited by 256
Alkondon, M., Pereira, E. F. R., Eisenberg, H. M., & Albuquerque, E. X. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00066.2000 · Cited by 248
“In addition, glutamate excitotoxicity—one of the possible mechanisms involved in the origin and/or progression of AD and PD (for review, see Dalack et al., 1998)—could be controlled by the nAChR-induced GABA release from interneurons in the human cerebral cortex.”
BackgroundBaker, A., Richmond, R., Haile, M., Lewin, T. J., Carr, V. J., Taylor, R. L., Jansons, S., & Wilhelm, K. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1934 · Cited by 255
Smoking and suicide: A brief overview
Hughes, J. R. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.06.003 · Cited by 236
Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.006 · Cited by 231
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Non?stimulant medications in the treatment of ADHD
Banaschewski, T., Roessner, V., Dittmann, R. W., Janardhanan Santosh, P., & Rothenberger, A. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1010-x · Cited by 183
“Central nicotinic activation stimulates the release of several neurotransmitters including dopamine, noradrenaline, acetylcholine, 5-hydroxytryptamine, gamma-aminobutyric acid (GABA) and endorphins [45, 109, 181] and has been shown to improve vigilance, attention and executive function [87, 101], probably by its norad…”
BackgroundCompton, M. T., Daumit, G. L., & Druss, B. G. (2006) · Harvard Review of Psychiatry · doi:10.1080/10673220600889256 · Cited by 177
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia
Marutle, A., Zhang, X., Court, J., Piggott, M., Johnson, M., Perry, R., Perry, E., & Nordberg, A. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00117-x · Cited by 175
Cigarette smoking and mortality risk in people with schizophrenia
Kelly, D. L., McMahon, R. P., Wehring, H. J., Liu, F., Mackowick, K. M., Boggs, D. L., Warren, K. R., Feldman, S., Shim, J.-C., Love, R. C., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp152 · Cited by 158
Cancer in schizophrenia: is the risk higher or lower?
Grinshpoon, A., Barchana, M., Ponizovsky, A., Lipshitz, I., Nahon, D., Tal, O., Weizman, A., & Levav, I. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.06.016 · Cited by 157
“This association is puzzling since it is contrary to the presence of risk factors noted in this population; for example, persons with schizophrenia smoke heavily (Dalack et al., 1998); rarely engage in physical exercise (Brown et al.”
BackgroundCortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153
Rüther, T., Bobes, J., De Hert, M., Svensson, T. H., Mann, K., Batra, A., Gorwood, P., & Möller, H. J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.11.002 · Cited by 149
“schizophrenia is the influence of nicotine on dopaminergic and glutamatergic receptor systems [55].”
BackgroundFowler, C. D., Arends, M. A., & Kenny, P. J. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830c360e · Cited by 131
“Similarly to anxiety disorders and depression, the rate of tobacco smoking is dramatically higher in schizophrenia patients compared with the general population (Masterson and O’Shea, 1984; Hughes et al., 1986; Goff et al., 1992; Dalack et al., 1998).”
BackgroundLevin, E. D., & Rezvani, A. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.019 · Cited by 129
“Antipsychotic drugs which cause greater cognitive impairment such as haloperidol cause increases in smoking while those with less detrimental effects decrease smoking [23,26,27].”
BackgroundReproductive patterns in psychotic patients
Laursen, T. M., & Munk-Olsen, T. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.018 · Cited by 111
Viana, J., Hannon, E., Dempster, E., Pidsley, R., Macdonald, R., Knox, O., Spiers, H., Troakes, C., Al-Saraj, S., Turecki, G., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw373 · Cited by 105
“For example, epidemiological data highlights a much higher rate of smoking in schizophrenia patients compared to unaffected controls (50,51).”
BackgroundComorbidity of psychiatric and substance abuse disorders
George, T. P., & Krystal, J. H. (2000) · Current Opinion in Psychiatry · doi:10.1097/00001504-200005000-00015 · Cited by 106
Laursen, T. M., & Nordentoft, M. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.04.027 · Cited by 93
Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins
Maher, M. P., Matta, J. A., Gu, S., Seierstad, M., & Bredt, D. S. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.001 · Cited by 64
Jablensky, A. (2003) · Schizophrenia · doi:10.1002/9780470987353.ch12 · Cited by 59
Gage, S. H., Jones, H. J., Taylor, A. E., Burgess, S., Zammit, S., & Munafò, M. R. (2017) · Scientific Reports · doi:10.1038/srep40653 · Cited by 57
Novak, G., Zai, C. C., Mirkhani, M., Shaikh, S., Vincent, J. B., Meltzer, H., Lieberman, J. A., Strauss, J., Lévesque, D., Kennedy, J. L., et al. (2010) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2010.00631.x · Cited by 23
“much more prevalent in patients with schizophrenia (Dalack et al. 1998), as well as in patients with bipolar disorder”
BackgroundCirculatory neurosteroid levels in smoking and non-smoking chronic schizophrenia patients
Iancu, I., Tchernihovsky, E., Maayan, R., Poreh, A., Dannon, P., Kotler, M., Weizman, A., & Strous, R. D. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.02.001 · Cited by 14
Metadata
- Authors
- Dalack, G. W., Healy, D. J., & Meador-Woodruff, J. H.
- Venue
- American Journal of Psychiatry
- Published
- 1998-11-01
- Volume
- 155
- Issue
- 11
- Pages
- 1490-1501
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2149445681
- Cited by
- 498
- References
- 92
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.